ArticleBiomedical optics express2012
Auto-fluorescence lifetime and light reflectance spectroscopy for breast cancer diagnosis: potential tools for intraoperative margin detection.
Article in Biomedical optics express, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 57 citations in OpenAlex.
- Time-Resolved Fluorescence and Diffuse Reflectance (TRF-DR) Spectroscopy for Heterogeneous Breast Tissue Classification and Tumor Margin Assessment.Journal of biophotonics · 2026Article
- Phasor theory of fluorescence lifetime imaging utilized on a maximum range of frequencies for prostate tissue analysis.Biomedical optics express · 2025Article
- Polarimetry terahertz imaging of human breast cancer surgical specimens.Journal of medical imaging (Bellingham, Wash.) · 2024Article
- Dual excitation spectral autofluorescence lifetime and reflectance imaging for fast macroscopic characterization of tissues.Biomedical optics express · 2024Article
- Point Projection Mapping System for Tracking, Registering, Labeling, and Validating Optical Tissue Measurements.Journal of imaging · 2024Article
- Fluorescence lifetime needle optical biopsy discriminates hepatocellular carcinoma.Biomedical optics express · 2022Article
- Mesoscopic fluorescence lifetime imaging: Fundamental principles, clinical applications and future directions.Journal of biophotonics · 2021Review
- Assessment of breast cancer surgical margins with multimodal optical microscopy: A feasibility clinical study.PloS one · 2021Article
- Feasibility Study of a Novel Protease-Activated Fluorescent Imaging System for Real-Time, Intraoperative Detection of Residual Breast Cancer in Breast Conserving Surgery.Annals of surgical oncology · 2020Article
- Development of a Robust Autofluorescence Lifetime Sensing Method for Use in an Endoscopic Application.Sensors (Basel, Switzerland) · 2020Article
- Real-time diagnosis and visualization of tumor margins in excised breast specimens using fluorescence lifetime imaging and machine learning.Biomedical optics express · 2020Article
- Topical dual-probe staining using quantum dot-labeled antibodies for identifying tumor biomarkers in fresh specimens.PloS one · 2020Article
- Real-time Visualization of Breast Carcinoma in Pathology Specimens From Patients Receiving Fluorescent Tumor-Marking Agent Tozuleristide.Archives of pathology & laboratory medicine · 2019Article
- Terahertz tomographic imaging of freshly excised human breast tissues.Journal of medical imaging (Bellingham, Wash.) · 2019Article
- Real-time, intraoperative detection of residual breast cancer in lumpectomy cavity walls using a novel cathepsin-activated fluorescent imaging system.Breast cancer research and treatment · 2018Article
- Method for accurate registration of tissue autofluorescence imaging data with corresponding histology: a means for enhanced tumor margin assessment.Journal of biomedical optics · 2018Article
- Automated detection of breast cancer in resected specimens with fluorescence lifetime imaging.Physics in medicine and biology · 2017Article
- Rapid diagnosis and intraoperative margin assessment of human lung cancer with fluorescence lifetime imaging microscopy.BBA clinical · 2017Article
- A Phantom Study of Terahertz Spectroscopy and Imaging of Micro- and Nano-diamonds and Nano-onions as Contrast Agents for Breast Cancer.Biomedical physics & engineering express · 2017Article
- Raman-Encoded Molecular Imaging with Topically Applied SERS Nanoparticles for Intraoperative Guidance of Lumpectomy.Cancer research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the use of two spectroscopic techniques, auto-fluorescence lifetime measurement (AFLM) and light reflectance spectroscopy (LRS), for detecting invasive ductal carcinoma (IDC) in human ex vivo breast specimens. AFLM used excitation at 447 nm with multiple emission wavelengths (532, 562, 632, and 644 nm), at which auto-fluorescence lifetimes and their weight factors were analyzed using a double exponent model. LRS measured reflectance spectra in the range of 500-840 nm and analyzed the spectral slopes empirically at several distinct spectral regions. Our preliminary results based on 93 measured locations (i.e., 34 IDC, 31 benign fibrous, 28 adipose) from 6 specimens show significant differences in 5 AFLM-derived parameters and 9 LRS-based spectral slopes between benign and malignant breast samples. Multinomial logistic regression with a 10-fold cross validation approach was implemented with selected features to classify IDC from benign fibrous and adipose tissues for the two techniques independently as well as for the combined dual-modality approach. The accuracy for classifying IDC was found to be 96.4 ± 0.8%, 92.3 ± 0.8% and 96 ± 1.3% for LRS, AFLM, and dual-modality, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.